UK markets closed

Sesen Bio, Inc. (SESN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6306+0.0170 (+2.77%)
At close: 04:00PM EST
0.6389 +0.01 (+1.32%)
After hours: 07:58PM EST

Sesen Bio, Inc.

245 First Street
Suite 1800
Cambridge, MA 02142
United States
617 444 8550

Full-time employees17

Key executives

NameTitlePayExercisedYear born
Dr. Thomas R. Cannell D.V.M.Pres, CEO & Director798.61kN/A1962
Ms. Monica ForbesCFO & Treasurer527.4kN/A1976
Dr. Glen C. MacDonaldChief Technology Officer512.27kN/A1951
Dr. Gregory L. Verdine Ph.D.Co-FounderN/AN/A1959
Ms. Elly RyuCorp. Controller & Principal Accounting OfficerN/AN/A1981
Ms. Erin ClarkVP of Corp. Strategy & Investor RelationsN/AN/AN/A
Mr. Mark R. SullivanGen. Counsel, Chief Compliance Officer & Corp. Sec.N/AN/A1971
Mr. Steve BarberaVP of Market AccessN/AN/AN/A
Dr. David BrooksSr. VP of Clinical Devel.N/AN/AN/A
Dr. Dennis Kim M.D., MPHChief Medical OfficerN/AN/A1969
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Sesen Bio, Inc.’s ISS governance QualityScore as of 28 January 2023 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.